• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients

  1. Pier Luigi Zinzani MD1,†,*,
  2. Alessandro Broccoli MD1,
  3. Vittorio Stefoni MD1,
  4. Gerardo Musuraca MD2,
  5. Elisabetta Abruzzese MD3,
  6. Amalia De Renzo MD4,
  7. Maria Cantonetti MD5,
  8. Francesco Bacci MD1,
  9. Michele Baccarani MD1,
  10. Stefano A. Pileri MD1

Article first published online: 24 AUG 2010

DOI: 10.1002/cncr.25307

Issue

Cancer

Cancer

Volume 116, Issue 24, pages 5667–5675, 15 December 2010

Additional Information

How to Cite

Zinzani, P. L., Broccoli, A., Stefoni, V., Musuraca, G., Abruzzese, E., De Renzo, A., Cantonetti, M., Bacci, F., Baccarani, M. and Pileri, S. A. (2010), Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. Cancer, 116: 5667–5675. doi: 10.1002/cncr.25307

Author Information

  1. 1

    Institute of Hematology and Medical Oncology L. e A. Seràgnoli, Policlinico Sant'Orsola-Malpighi, University of Bologna, Bologna, Italy

  2. 2

    Romagna Scientific Institute for the Study and the Treatment of Tumors (IRST), Meldola, Forli, Italy

  3. 3

    Division of Hematology, S. Eugenio Hospital, Rome, Italy

  4. 4

    Department of Hematology, Federico II University, Naples, Italy

  5. 5

    Department of Hematology, University Tor Vergata, Rome, Italy

  1. †

    Fax: (011) 39 051 636 4037

*Institute of Hematology and Medical Oncology L. e A. Seràgnoli Policlinico Sant'Orsola-Malpighi, University of Bologna, Via Massarenti, 9-40138 Bologna, Italy

  1. †

    Fax: (011) 39 051 636 4037

Publication History

  1. Issue published online: 3 DEC 2010
  2. Article first published online: 24 AUG 2010
  3. Manuscript Accepted: 26 JAN 2010
  4. Manuscript Revised: 23 DEC 2009
  5. Manuscript Received: 30 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (212K)

REFERENCES

  • 1
    Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue Systems. 4th ed. Lyon, France: IARC; 2008.
  • 2
    Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005; 106: 1164-1174.
  • 3
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329: 987-994.
  • 4
    Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103: 275-282.
  • 5
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-511.
  • 6
    Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 1937-1947.
  • 7
    Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005; 18: 1377-1384.
  • 8
    Zinzani PL, Dirnhofer S, Sabattini E, et al. Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica. 2005; 90: 341-347.
  • 9
    Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359: 2313-2323.
  • 10
    Zinzani PL, Barbieri E, Visani G, et al. Ifosfamide, epirubicin, and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Haematologica. 1994; 79: 508-512.
  • 11
    Fleming TR. One-sample multiple testing procedure for phase 2 clinical trials. Biometrics. 1982; 38: 143-151.
  • 12
    Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. Oxford, UK: Blackwell; 1987.
  • 13
    A'Hern RP. Sample size tables for exact single-stage phase 2 designs. Stat Med. 2001; 20: 859-866.
    Direct Link:
  • 14
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an International Workshop to Standardize Response Criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 1244-1253.
  • 15
    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.
  • 16
    Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 17
    Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992; 327: 1342-1349.
  • 18
    Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol. 1994; 12: 769-778.
  • 19
    Fisher RI, Gaynor ER, Dahlberg S, et al. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994; 5 (suppl): S91-S95.
  • 20
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346: 235-242.
  • 21
    Habermann TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood. 2003; 102: 6.
  • 22
    Pfreundschuh M, Trumper L, Gill D, et al. First analysis of the completed Mabthera International (MInT) trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favourable subgroup with IPI = 0 and no bulky disease. Blood. 2004; 104: 48.
  • 23
    Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol —a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol. 2000; 18: 3025-3030.
  • 24
    Gisselbrecht G, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002; 20: 2472-2479.
  • 25
    Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003; 21: 1255-1262.
  • 26
    Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol. 2002; 20: 4413-4419.
  • 27
    Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med. 1995; 332: 1045-1051.
  • 28
    Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med. 2004; 350: 1828-1837.
  • 29
    van Imhoff GW, Boerma E-JG, van der Holt B, et al. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24: 4135-4142.
  • 30
    Nyman H, Adde M, Karjalainen-Lindsberg M-L, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007; 109: 4930-4935.
  • 31
    Veelken H, Vik Dannheim S, Schulte Moenting J, Martens UM, Finke J, Schmitt-Graeff A. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol. 2007; 18: 931-939.
  • 32
    Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009; 113: 6069-6076.
  • 33
    Nowakowski GS, LaPlant B, Habermann T, et al. A phase I/II trial of lenalidomide and RCHOP (R2CHOP) in patients with newly diagnosed diffuse large B-cell (DLBCL) and follicular grade 3 lymphoma. Blood. 2009; 114: 666.
  • 34
    Reeder C, Gornet MK, Habermann TM, et al. A phase 2 trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed aggressive non-Hodgkin lymphoma (NHL). Blood. 2007; 110.
View Full Article (HTML) Get PDF (212K)